e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): July 1, 2009
Repros Therapeutics Inc.
(Exact name of registrant as specified in its charter)
         
Delaware   001-15281   76-0233274
         
(State or other jurisdiction of   (Commission File Number)   (I.R.S. Employer Identification No.)
incorporation or organization)        
2408 Timberloch Place, Suite B-7
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant’s telephone
number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 8.01 — Other Events
     On July 1, 2009 Repros Therapeutics, Inc. issued a press release titled “Repros Therapeutics Inc. Provides Update for Proellex® Clinical Program,” a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 — Financial Statements and Exhibits
     (d) Exhibits
         
Exhibit    
Number   Description
  99.1    
Press Release dated July 1, 2009

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
             
    Repros Therapeutics Inc.    
 
            
Date: July 2, 2009.
            
 
            
 
  By:   /s/ Louis Ploth, Jr.
 
Louis Ploth, Jr. 		   
 
      Chief Financial Officer    

 

 

EXHIBIT INDEX
         
Exhibit    
Number   Description
  99.1    
Press Release dated July 1, 2009